Sunshine Biopharma Inc.
Sunshine Biopharma Inc. is a U.S.-based pharmaceutical company organized around generic prescription drugs, over-the-counter supplements, and proprietary drug development. Through its Canadian subsidiaries, it markets and distributes a broad portfolio of medicines in Canada while also advancing early-stage oncology and antiviral candidates.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaBranded and unbranded generic medicines sold in Canada through Nora Pharma.
Products sold under distribution agreements where the company acts as distributor and earns a sales share or margin.
Health supplements and nutraceutical products sold through Sunshine Biopharma Canada.
Early-stage internal pipeline assets including K1.1 and SBFM-PL4.
Asiakkaat
The company sells primarily into the Canadian pharmaceutical supply chain, with pharmacies and other drug purchasers buying generic prescription medicines for everyday therapeutic use. It also serves partners in distribution and licensing arrangements, where third-party manufacturers or rights holders use the company to commercialize products in Canada. Its pipeline programs are aimed at future patients and healthcare providers in oncology and antiviral indications.
Buy generic prescription drugs for dispensing to patients and rely on supply continuity and regulatory approval.
Provide product rights or supply arrangements that the company commercializes in Canada.
Purchase OTC products such as Essential•9, Calcium-Vitamin D, L-Citrulline, and Taurine.
Represent the eventual end market for proprietary oncology and antiviral candidates.
Strategia
The company’s strategy is to expand its Canadian generic-drug portfolio through in-licensing, cross-licensing, and distribution agreements while adding OTC products under its own authorizations. It also seeks to build a proprietary pipeline in oncology and antivirals, giving the business a longer-dated source of value beyond the commercial generic portfolio. Regulatory approvals, dossier ownership, and product breadth are central to its plan to deepen pharmacy access and broaden its product mix.
A wider portfolio improves pharmacy access and strengthens the company’s position with buyers.
Internal drug candidates can create differentiated long-term upside beyond generic distribution.
Better sourcing and product mix can improve the economics of the distributor model.
Maantiede
Sunshine Biopharma is headquartered in the United States but its commercial footprint is centered in Canada through Nora Pharma and Sunshine Biopharma Canada. The company’s disclosed operations emphasize the Canadian generic drug market, while its proprietary licensing and development activities have a broader international character. Geography matters because Canadian regulatory approvals, product dossiers, and distribution relationships are central to how the business monetizes its portfolio.
Riskit
The business depends on regulatory approvals, product dossier execution, and third-party supply arrangements, which can delay launches or limit commercialization. It also faces typical pharmaceutical risks such as pricing pressure in generics, product concentration, and development risk in early-stage pipeline assets. Intangible asset impairment and the need for additional capital are important company-specific risks because they can affect reported results and funding flexibility.
Products must be approved by Health Canada before commercialization, which can delay launches.
Kohdistuu: Canadian generic portfolio and new product launches
Many products are sourced through in-licenses, cross-licenses, or distribution agreements.
Kohdistuu: Generic prescription and distribution-based products
Product licenses may not be commercializable, requiring write-downs.
Kohdistuu: Licensed product dossiers and acquired rights
R&D and expansion can require external funding if operating cash is insufficient.
Kohdistuu: Corporate liquidity and growth plans
K1.1 and SBFM-PL4 are early-stage and may not reach commercialization.
Kohdistuu: Proprietary R&D
Kirjanpito
Harkinnanvaraiset erätThe company acts as distributor on some products, so principal-agent and timing judgments affect reported sales.
Vaikutus: Can change gross revenue, net revenue, and margin presentation
Management disclosed an impairment tied to product licenses that could not be commercialized.
Vaikutus: Can materially reduce earnings and asset carrying values
Procurement costs and product mix affect direct costs and gross profit.
Vaikutus: Affects gross margin and quarter-to-quarter comparability
Acquired dossiers and rights require judgment on useful life and recoverability.
Vaikutus: Can influence amortization and impairment charges
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Quantum Biopharma Ltd.
QNTM · Pharmaceutical Preparations
GT Biopharma, Inc.
GTBP · Pharmaceutical Preparations
LakeShore Biopharma Co., Ltd.
LSBCF · Pharmaceutical Preparations
Regen BioPharma Inc
RGBPP · Pharmaceutical Preparations
Regen BioPharma Inc is a U.S.-based biopharmaceutical development company organized in Nevada and operating through its wholly owned subsidiary KCL Therapeutics, Inc.
Sutro Biopharma, Inc
STRO · Biological Products, (No Diagnostic Substances)
Sutro Biopharma is a U.S.-based biopharmaceutical company that develops therapeutic biologics using its XpressCF® and XpressCF+® cell-free protein synthesis platforms.
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Päivitetty: 24.9.2026